NR606 Week 8 Final Exam Due 26 April
2026 Diagnosis and Management in
Psychiatric-Mental Health II Practicum -
PMHNP- 1-75 ACTUAL EXAM QUESTIONS
AT Chamberlain University..pdf
Core Domains:
• Attention-Deficit/Hyperactivity Disorder (ADHD) Across the Lifespan
• Disruptive, Impulse-Control, and Conduct Disorders (ODD, Conduct
Disorder, DMDD)
• Trauma- and Stressor-Related Disorders (PTSD, ASD, Adjustment
Disorders)
• Bipolar and Related Disorders
• Schizophrenia Spectrum and Other Psychotic Disorders
• Eating Disorders (Anorexia Nervosa, Bulimia Nervosa, Binge-Eating
Disorder)
• Substance Use Disorders and Addictions
• Psychopharmacology and Medication Management
• Special Populations (Children, Adolescents, LGBTQ+, Veterans)
• Ethical and Legal Considerations in Psychiatric Practice
Introduction
,This comprehensive examination is designed for NR606 Diagnosis and
Management in Psychiatric-Mental Health II Practicum students preparing
for the Week 8 Final Exam at Chamberlain University. The assessment
evaluates the advanced practice psychiatric-mental health nurse
practitioner student's mastery of diagnostic criteria, evidence-based
treatment modalities, and psychopharmacological management across the
lifespan. Through multiple-choice questions and clinical scenarios
spanning Weeks 5-8 content—including ADHD, disruptive disorders,
trauma-related conditions, bipolar disorder, psychotic disorders, eating
disorders, and substance use disorders—students are challenged to
integrate DSM-5-TR diagnostic criteria, clinical decision-making, and
ethical considerations. Updated for the 2026/2027 academic year, this
resource reflects current evidence-based guidelines. Successful
completion demonstrates readiness for independent PMHNP practice.
SECTION ONE: QUESTIONS 1–75
Question 1
A 9-year-old male is diagnosed with ADHD, predominantly hyperactive-
impulsive type. Which of the following is the first-line pharmacological
treatment according to current clinical guidelines?
A. Atomoxetine (Strattera)
B. Fluoxetine (Prozac)
C. Guanfacine (Intuniv)
D. Methylphenidate (Ritalin)
D. Methylphenidate (Ritalin)
RATIONALE: Stimulants like methylphenidate are considered first-
line treatments for pediatric ADHD due to their high efficacy rates in
reducing core symptoms. Non-stimulants like atomoxetine are typically
reserved for patients who do not tolerate stimulants or have a history of
,substance abuse. It is essential for the PMHNP to monitor growth and
cardiovascular health throughout the duration of stimulant therapy.
Question 2
A patient taking clozapine for treatment-resistant schizophrenia presents
for their weekly lab work. Which Absolute Neutrophil Count (ANC)
result would require the immediate discontinuation of the medication?
A. 950/mm³
B. 1600/mm³
C. 1800/mm³
D. 2000/mm³
A. 950/mm³
RATIONALE: An ANC below 1000/mm³ is classified as severe
neutropenia and requires immediate cessation of clozapine therapy to
prevent life-threatening infections. The Clozapine REMS program
mandates frequent monitoring to catch agranulocytosis in its early
stages. The PMHNP must report these values and follow the specific
protocol for re-challenging or permanent discontinuation.
Question 3
A child on guanfacine ER develops symptomatic bradycardia (HR 52)
and lightheadedness. What is the best next step?
A. Increase the dose
B. Hold the medication and obtain an ECG
C. Add a stimulant to increase heart rate
D. Continue the medication; symptoms will resolve
B. Hold the medication and obtain an ECG
, RATIONALE: α₂ agonists (guanfacine, clonidine) can cause
symptomatic bradycardia and heart block. The medication should be
held immediately and an ECG obtained to evaluate for conduction
abnormalities.
Question 4
A 28-year-old female with Bipolar I Disorder is prescribed lithium
carbonate. Which laboratory test should be performed at baseline and
monitored regularly to assess for potential long-term toxicity?
A. Serum Creatinine and BUN
B. Liver Function Tests (LFTs)
C. Hemoglobin A1c
D. Prothrombin Time (PT)
A. Serum Creatinine and BUN
RATIONALE: Lithium can cause nephrogenic diabetes insipidus and
chronic kidney disease with long-term use. Renal function should be
assessed at baseline and monitored regularly. Liver function tests,
HbA1c, and PT are not primary monitoring parameters for lithium
therapy.
Question 5
A PMHNP is evaluating a veteran for PTSD. The patient reports frequent,
debilitating nightmares. Which medication is specifically recommended
to target this symptom?
A. Risperidone
B. Prazosin
C. Alprazolam
D. Trazodone
B. Prazosin
2026 Diagnosis and Management in
Psychiatric-Mental Health II Practicum -
PMHNP- 1-75 ACTUAL EXAM QUESTIONS
AT Chamberlain University..pdf
Core Domains:
• Attention-Deficit/Hyperactivity Disorder (ADHD) Across the Lifespan
• Disruptive, Impulse-Control, and Conduct Disorders (ODD, Conduct
Disorder, DMDD)
• Trauma- and Stressor-Related Disorders (PTSD, ASD, Adjustment
Disorders)
• Bipolar and Related Disorders
• Schizophrenia Spectrum and Other Psychotic Disorders
• Eating Disorders (Anorexia Nervosa, Bulimia Nervosa, Binge-Eating
Disorder)
• Substance Use Disorders and Addictions
• Psychopharmacology and Medication Management
• Special Populations (Children, Adolescents, LGBTQ+, Veterans)
• Ethical and Legal Considerations in Psychiatric Practice
Introduction
,This comprehensive examination is designed for NR606 Diagnosis and
Management in Psychiatric-Mental Health II Practicum students preparing
for the Week 8 Final Exam at Chamberlain University. The assessment
evaluates the advanced practice psychiatric-mental health nurse
practitioner student's mastery of diagnostic criteria, evidence-based
treatment modalities, and psychopharmacological management across the
lifespan. Through multiple-choice questions and clinical scenarios
spanning Weeks 5-8 content—including ADHD, disruptive disorders,
trauma-related conditions, bipolar disorder, psychotic disorders, eating
disorders, and substance use disorders—students are challenged to
integrate DSM-5-TR diagnostic criteria, clinical decision-making, and
ethical considerations. Updated for the 2026/2027 academic year, this
resource reflects current evidence-based guidelines. Successful
completion demonstrates readiness for independent PMHNP practice.
SECTION ONE: QUESTIONS 1–75
Question 1
A 9-year-old male is diagnosed with ADHD, predominantly hyperactive-
impulsive type. Which of the following is the first-line pharmacological
treatment according to current clinical guidelines?
A. Atomoxetine (Strattera)
B. Fluoxetine (Prozac)
C. Guanfacine (Intuniv)
D. Methylphenidate (Ritalin)
D. Methylphenidate (Ritalin)
RATIONALE: Stimulants like methylphenidate are considered first-
line treatments for pediatric ADHD due to their high efficacy rates in
reducing core symptoms. Non-stimulants like atomoxetine are typically
reserved for patients who do not tolerate stimulants or have a history of
,substance abuse. It is essential for the PMHNP to monitor growth and
cardiovascular health throughout the duration of stimulant therapy.
Question 2
A patient taking clozapine for treatment-resistant schizophrenia presents
for their weekly lab work. Which Absolute Neutrophil Count (ANC)
result would require the immediate discontinuation of the medication?
A. 950/mm³
B. 1600/mm³
C. 1800/mm³
D. 2000/mm³
A. 950/mm³
RATIONALE: An ANC below 1000/mm³ is classified as severe
neutropenia and requires immediate cessation of clozapine therapy to
prevent life-threatening infections. The Clozapine REMS program
mandates frequent monitoring to catch agranulocytosis in its early
stages. The PMHNP must report these values and follow the specific
protocol for re-challenging or permanent discontinuation.
Question 3
A child on guanfacine ER develops symptomatic bradycardia (HR 52)
and lightheadedness. What is the best next step?
A. Increase the dose
B. Hold the medication and obtain an ECG
C. Add a stimulant to increase heart rate
D. Continue the medication; symptoms will resolve
B. Hold the medication and obtain an ECG
, RATIONALE: α₂ agonists (guanfacine, clonidine) can cause
symptomatic bradycardia and heart block. The medication should be
held immediately and an ECG obtained to evaluate for conduction
abnormalities.
Question 4
A 28-year-old female with Bipolar I Disorder is prescribed lithium
carbonate. Which laboratory test should be performed at baseline and
monitored regularly to assess for potential long-term toxicity?
A. Serum Creatinine and BUN
B. Liver Function Tests (LFTs)
C. Hemoglobin A1c
D. Prothrombin Time (PT)
A. Serum Creatinine and BUN
RATIONALE: Lithium can cause nephrogenic diabetes insipidus and
chronic kidney disease with long-term use. Renal function should be
assessed at baseline and monitored regularly. Liver function tests,
HbA1c, and PT are not primary monitoring parameters for lithium
therapy.
Question 5
A PMHNP is evaluating a veteran for PTSD. The patient reports frequent,
debilitating nightmares. Which medication is specifically recommended
to target this symptom?
A. Risperidone
B. Prazosin
C. Alprazolam
D. Trazodone
B. Prazosin
